Grant Awarded to Study Motor Recovery in Stroke Survivors

Translate to Spanish or other 102 languages!

Dr. Michael R. Dobbs, chair of the Department of Neurology, UTRGV School of Medicine, and Dr. Kelsey Baker, assistant professor, Department of Neuroscience, UTRGV School of Medicine. (UTRGV Photos)
Dr. Michael R. Dobbs, chair of the Department of Neurology, UTRGV School of Medicine, and Dr. Kelsey Baker, assistant professor, Department of Neuroscience, UTRGV School of Medicine. (UTRGV Photos)

Mega Doctor News

- Advertisement -

By Maria Gonzalez

RIO GRANDE VALLEY, Texas – Dr. Michael R. Dobbs, professor and chair of the Department of Neurology in the UTRGV School of Medicine, has been awarded a $443,963 grant to research the motor recovery, along with the brain and spine degeneration, of 30 stroke survivors over the next three years. 

The grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), which is part of the federal government’s National Institutes of Health (NIH).  

- Advertisement -

Dobbs said the R15 NIH grant will allow him to study whether degeneration after a stroke affects some areas of the brain more progressively than others, and whether that degeneration extends to the level of the spinal cord. 

“We want to determine how this degeneration impacts the ability to move the first three months after a stroke,” Dobbs said.

The project, titled “Role of Alternative Sensorimotor Pathway Degeneration in Motor Function of in Acute Stroke,” will be led by principal investigator Dobbs, and co-PI Dr. Kelsey Baker, assistant professor in the Department of Neuroscience at the UTRGV School of Medicine. 

Baker said it is estimated that, by 2030, an additional 3.4 million adults will experience a stroke.

- Advertisement -

“White Hispanic males are projected to experience the highest rates,” she said, “In addition, preliminary estimates from our work suggest that stroke is a particular concern in South Texas and the Rio Grande Valley.” 

Dr. Thomas Spencer, associate vice president for UTRGV’s Division of Research, said the division fully supports the work Dobbs and his research team are doing.

“Their search for advancements in the diagnosis and treatment of patients needing neurological care is important – and in many cases critical – not just to patients in the Valley, but around the world,” he said.

This federal funding will provide the means to collect high-resolution and advanced neuroimaging protocols (MRI) through one of the first studies to capture neuronal pathway changes in the spinal cord in acute stroke. The study will be conducted at the newly established UTRGV Institute of Neuroscience in Harlingen. 

NEUROLOGY AND NEUROSCIENCE TRAINING FOR THE NEXT GENERATION

NIH grant reviewers called the grant application “a highly translational application from an experienced clinician-scientist that could produce some intriguing new clinical science for stroke survivors, while creating an outstanding training opportunity for students at UTRGV…” 

Dobbs said this Research Enhancement Award Program (REAP) project will provide a valuable opportunity for medical students to be exposed to hypothesis-driven research within the Valley. It also will enhance the UTRGV-NIH research portfolio and provide medical students and undergraduate students opportunities to be at the forefront of research data collection and presentation. 

“Additionally, the work will lead to publications in scientific journals,” Dobbs said, “and could lead to additional funded projects through other NIH mechanisms.”    

The grant lasts through March 31, 2025. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

STHS Children’s Marks 20th Anniversary with Gala Honoring Pediatric Providers Behind Its Success

For the past 20 years, South Texas Health System Children’s has stood as a place where compassionate care and clinical excellence come together to create hope for children and their families.
- Advertisement -